Aptevo Therapeutics (APVO) vs GeoVax Labs (GOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aptevo Therapeutics is the larger company by market cap ($3.2 million vs $2.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | GOVX |
|---|---|---|
| Share price | $1.79 | $0.281 |
| Market cap | $3.24M | $2.84M |
| 1-day change | -0.56% | -1.95% |
| P/E ratio (TTM) | 0.03 | — |
| EPS (TTM) | $66.96 | $-8.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.14 | $15.75 |
| 52-week low | $1.37 | $0.2705 |
| Distance from 52-week high | -94.25% | -98.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +1324.58% | +3458.72% |
| Average volume | 91.51K | 771.47K |
| Shares outstanding | 1.81M | 10.10M |
| Employees | 33 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
APVO vs GOVX FAQ
Which is bigger, Aptevo Therapeutics or GeoVax Labs?
Aptevo Therapeutics (APVO) is larger, with a market capitalization of $3.24M compared with $2.84M for GeoVax Labs (GOVX).
Are Aptevo Therapeutics and GeoVax Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.